$36.60
0.34[0.94%]
Last update: 2:49PM Get Real Time Here
Celldex Therapeutics
(NASDAQ:CLDX)Celldex Therapeutics Stock (NASDAQ:CLDX), Analyst Ratings, Price Targets, Predictions
Celldex Therapeutics Inc has a consensus price target of $58.38, established from looking at the 29 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Cantor Fitzgerald, and Guggenheim on April 17, 2024, March 22, 2024, and February 27, 2024. With an average price target of $79 between HC Wainwright & Co., Cantor Fitzgerald, and Guggenheim, there's an implied 115.85% upside for Celldex Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Cantor Fitzgerald
Guggenheim
TD Cowen
Wells Fargo
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Celldex Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/17/2024 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 118.58% | HC Wainwright & Co. | Joseph Pantginis | → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 83.06% | Cantor Fitzgerald | Kristen Kluska | → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 02/27/2024 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 145.9% | Guggenheim | Yatin Suneja | $72 → $90 | Maintains | Buy | Get Alert |
| 12/20/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | — | TD Cowen | Yaron Werber | — | Initiates | → Outperform | Get Alert |
| 11/10/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | -26.23% | Wells Fargo | Derek Archila | → $27 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/06/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 118.58% | HC Wainwright & Co. | Joseph Pantginis | $73 → $80 | Maintains | Buy | Get Alert |
| 11/03/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 42.08% | Cantor Fitzgerald | Kristen Kluska | $54 → $52 | Maintains | Overweight | Get Alert |
| 10/12/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 47.54% | Cantor Fitzgerald | Kristen Kluska | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 09/27/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 47.54% | Cantor Fitzgerald | Kristen Kluska | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | -42.62% | Wells Fargo | Derek Archila | → $21 | Initiates | → Underweight | Get Alert |
| 08/16/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 47.54% | Cantor Fitzgerald | Kristen Kluska | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 08/10/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 99.45% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 99.45% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 99.45% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 99.45% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 47.54% | Cantor Fitzgerald | Kristen Kluska | $55 → $54 | Maintains | Overweight | Get Alert |
| 05/05/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 99.45% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
| 03/22/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 99.45% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | CLDX | Buy Now | Celldex Therapeutics | $36.60 | 99.45% | HC Wainwright & Co. | Joseph Pantginis | → $73 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Celldex Therapeutics (CLDX)?
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by HC Wainwright & Co. on April 17, 2024. The analyst firm set a price target for $80.00 expecting CLDX to rise to within 12 months (a possible 118.58% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Celldex Therapeutics (CLDX)?
The latest analyst rating for Celldex Therapeutics (NASDAQ: CLDX) was provided by HC Wainwright & Co., and Celldex Therapeutics reiterated their buy rating.
When was the last upgrade for Celldex Therapeutics (CLDX)?
The last upgrade for Celldex Therapeutics Inc happened on November 10, 2023 when Wells Fargo raised their price target to $27. Wells Fargo previously had an underweight for Celldex Therapeutics Inc.
When was the last downgrade for Celldex Therapeutics (CLDX)?
There is no last downgrade for Celldex Therapeutics.
When is the next analyst rating going to be posted or updated for Celldex Therapeutics (CLDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celldex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celldex Therapeutics was filed on April 17, 2024 so you should expect the next rating to be made available sometime around April 17, 2025.
Is the Analyst Rating Celldex Therapeutics (CLDX) correct?
While ratings are subjective and will change, the latest Celldex Therapeutics (CLDX) rating was a reiterated with a price target of $0.00 to $80.00. The current price Celldex Therapeutics (CLDX) is trading at is $36.60, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.